MedTrace Logo

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-02-15

No results posted yet for this study

Summary

The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

GSBR-1290 (Capsule/Tablet)

Participants will receive GSBR-1290 oral capsules or tablets.

DRUG

GSBR-1290

Participants will receive GSBR-1290 oral tablets.

DRUG

Placebo

Participants will receive matching-placebo oral tablets.

DRUG

Placebo (Capsule/Tablet)

Participants will receive matching-placebo oral capsules or tablets.

Sponsors & Collaborators

  • Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06139055 on ClinicalTrials.gov